资讯

Targeted Oncology4 小时
Tagraxofusp Yields Deep Responses as Frontline BPDCN Therapy
During a live event, Gary J. Schiller, MD, explored the outcomes of the phase 1/2 trial of tagraxofusp-erzs in patients with ...
Targeted Oncology7 小时
AMPLITUDE Trial: What Community Oncologists Should Know
Discover the groundbreaking AMPLITUDE trial results, showcasing niraparib's effectiveness in treating metastatic prostate cancer with minimal safety concerns.
Targeted Oncology9 小时
OS Therapies Seeks FDA RMAT Status for OST-HER2 in Pediatric Osteosarcoma
Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...
Targeted Oncology12 小时
FDA Grants Priority Review for Lurbinectedin/Atezolizumab in ES-SCLC
Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...